Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Journal: Annals of neurology
Published: December 20, 2022
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 09, 2021
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.
Journal: Muscle & nerve
Published: February 17, 2021
Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.
Journal: Multiple sclerosis and related disorders
Published: December 11, 2020
Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
Journal: Annals of clinical and translational neurology
Published: November 17, 2020
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
Journal: Multiple sclerosis and related disorders
Published: October 07, 2020
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Journal: Annals of neurology
Published: September 23, 2020
Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study.
Journal: Frontiers in neurology
Published: April 27, 2020
Consistent improvement with eculizumab across muscle groups in myasthenia gravis.
Journal: Annals of clinical and translational neurology
Published: April 14, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026